Press Release October 07, 2020

CRISPR Co-Founder Dr. Emmanuelle Charpentier Receives 2020 Nobel Prize in Chemistry

The Royal Swedish Academy of Sciences awarded Dr. Emmanuelle Charpentier the 2020 Nobel Prize in Chemistry for her groundbreaking work on the CRISPR/Cas9 system, a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. 

Charpentier co-founded Goodwin client CRISPR Therapeutics together with Rodger Novak and Shaun Foy. She is Founding, Scientific and Managing Director of the Max Planck Unit for the Science of Pathogens and Honorary Professor at Humboldt University, Berlin, Germany. The prize was also awarded to Jennifer Doudna, Professor of Molecular and Cell Biology and Professor of Chemistry at the University of California, Berkeley and Investigator of the Howard Hughes Medical Institute.

In the announcement from the Royal Swedish Academy of Sciences, Professor Claes Gustafsson, Chair of the Nobel Committee for Chemistry commented: “There is enormous power in this genetic tool, which affects us all. It has not only revolutionized basic science but also resulted in innovative crops and will lead to groundbreaking new medical treatments.”  

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

Please join us in congratulating Charpentier on this distinguished honor and the team at CRISPR Therapeutics for their transformative scientific achievement.

For more details, read the press release.